2023
Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts
Gonsalves G, Paltiel A, Thornhill T, DeMaria A, Cranston K, Klevens R, Warren J. Patterns of Infectious Disease Associated With Injection Drug Use in Massachusetts. Clinical Infectious Diseases 2023, 76: 2134-2139. PMID: 36757712, PMCID: PMC10273381, DOI: 10.1093/cid/ciad073.Peer-Reviewed Original ResearchConceptsSoft tissue infectionsHuman immunodeficiency virusHepatitis C virusInjection drug useHCV casesInfective endocarditisHIV casesDrug useSubstance use disordersLogistic regression modelsClinical sequalaeSSTI casesPublic health crisisTissue infectionsImmunodeficiency virusDisease AssociatedHIV outbreakAbscess incisionC virusUse disordersInfectious diseasesInfectionMultiple outbreaksMedical proceduresSuch associations
2020
Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out
Marcus JL, Paltiel AD, Walensky RP. Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. Clinical Infectious Diseases 2020, 71: 3152-3153. PMID: 32097454, PMCID: PMC7819505, DOI: 10.1093/cid/ciz1236.Peer-Reviewed Original Research
2019
The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India
Kazemian P, Costantini S, Kumarasamy N, Paltiel AD, Mayer KH, Chandhiok N, Walensky RP, Freedberg KA. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clinical Infectious Diseases 2019, 70: 633-642. PMID: 30921454, PMCID: PMC7319272, DOI: 10.1093/cid/ciz249.Peer-Reviewed Original ResearchConceptsHIV testing strategiesPreexposure prophylaxisHIV incidenceCost-effective HIV prevention strategyHuman immunodeficiency virus (HIV) preexposure prophylaxisHuman immunodeficiency virus (HIV) epidemicQuarterly HIV testingHigh HIV incidenceHigh-risk groupHIV prevention strategiesIndia-specific dataWorld Health OrganizationIndian MSMRoutine HIVHIV testHIV testingTesting strategiesPWIDPrevention strategiesHIVMean incidenceGross domestic productPrEPMSMHealth Organization
2016
Authors' Reply
Luz PM, Grinsztejn B, Veloso VG, Paltiel AD. Authors' Reply. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 71: e56. PMID: 26579987, PMCID: PMC4712134, DOI: 10.1097/qai.0000000000000902.Peer-Reviewed Original Research
2015
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 152-161. PMID: 25415289, PMCID: PMC4294967, DOI: 10.1097/qai.0000000000000426.Peer-Reviewed Original ResearchConceptsGenotype resistance testingART initiationAntiretroviral treatmentART costsGenotype testingEvandro Chagas Clinical Research InstituteResistance prevalenceFirst-line ART initiationHIV Clinical CohortHIV treatment guidelinesIncremental cost-effectiveness ratioBaseline patient characteristicsEffective antiretroviral treatmentART-naive individualsLife expectancyClinical Research InstituteCost-effectiveness ratioImmune recoveryCD4 countViral suppressionHIV diseasePatient characteristicsTreatment guidelinesMean agePrimary resistance
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccine
2005
Routine human immunodeficiency virus testing: An economic evaluation of current guidelines
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. The American Journal Of Medicine 2005, 118: 292-300. PMID: 15745728, DOI: 10.1016/j.amjmed.2004.07.055.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHIV prevalenceCurrent guidelinesHuman immunodeficiency virus (HIV) counselingMean quality-adjusted life expectancyHIV Screening ProgramQuality-adjusted life expectancyLife-sustaining careOverall participation rateCost-effectiveness analysisUndiagnosed infectionHIV screeningHIV counselingClinical effectsReferral guidelinesPrevention guidelinesInfected patientsScreening programDisease controlPrevalenceU.S. hospitalsScreening thresholdLife expectancyHIVPatients
1991
Modeling zidovudine therapy: a cost-effectiveness analysis.
Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 795-804. PMID: 1906934.Peer-Reviewed Original Research